{"input_url":"https://www.pharmtech.com/view/peptide-compounding-vote-raises-questions-drug-developers","gnews_decode":"https://www.pharmtech.com/view/peptide-compounding-vote-raises-questions-drug-developers","http_status":200,"final_url":"https://www.pharmtech.com/view/peptide-compounding-vote-raises-questions-drug-developers","html_length":444738,"trafilatura_result":"ok","text_length":4975,"text_preview":"Peptide Compounding Vote Raises New Questions for Drug Developers\nKey Takeaways\n- Narrow votes favored adding BPC-157, KPV, and TB-500 to the compounding list, with MOTs-C also recommended, signaling potential near-term changes in legal supply channels.\n- Online “research-use” peptide distribution h","verdict":"OK"}